Mj. Alcorn et al., Selection of CD34(+) cells from cryopreserved PBPC can be significantly improved by the addition of recombinant human DNase (Pulmozyme), CYTOTHERAPY, 1(1), 1999, pp. 31-40
Citations number
29
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Background
It has been reported previously that PBPC can be recovered from cyropreserv
ation and can be efficiently CD34-selected, to provide a product of high pu
rity (> 80% CD34) with good yield ( > 50% recovery).
Methods
In this study, we have investigated the effects of thawing and CD34-selecti
ng cyopreserved PBPC in the presence of recombinant human deoxyribonuclease
(rhDNase; Pulmozyme) and magnesium chloride (MgCl2 injection)
Results
The addition of Pulmozyme and MgCl2 significantly improves the yield of CD3
4(+) cells, compared with the standard procedure (65.2% and 39.7%, respecti
vely). Following CD34 selection, significantly greater. recovery of CFC in
the selected fraction can be obtained from Pulmozyme-treated cells, compare
d with standard cells. The use of recombinant human Pulmozyme and i.v. grad
e MgCl2 should facilitate the application of this procedure to the clinical
setting. CD34(+) cells selected from cryopreserved PBPC, can in turn be cr
yopreserved for a second time. When thawed, these cells still retained good
viability (>80%).
Discussion
Cells originally processed in the presence of Pulmozyme gave significantly
superior yields of CD34(+) cells and CFC compared with standard cells. The
functional ability of these CD34(+) cells was demonstrated futher in art ex
vivo expansion culture system with extensive proliferation of cells and CF
C. In addition, the presence of significant numbers of primitive hemopoieti
c cells could be readily demonstrated in a cobblestone-area forming assay.